However, in a phase II clinical trial, was reported that carlumab (anti-CCL2 mAb) in patients with metastatic castration-resistant prostate cancer, induced a rapid rebound of the circulating concentration of free CCL2 to value higher than the pretreatment serum levels (45). This evidence concerns the gene CCL2 and prostate carcinoma.